 Subjects will be housed in the Celerion clinic from at least 24 hours prior from Day 2, until 48 hours after dosing. Subjects will return for subsequent follow up safety and PK assessments on Days 4 to 7 and will be contacted via a phone call for followup questioning about adverse events 7 days later Study Day 14. One cohort will return after a washout of at least 14 days or five halflives whichever is longer of their fasting dose to receive the same intermediate dose TBD mg under fed conditions. 